University of Miami Division of Clinical Pharmacology therapeutic rounds: Irritable bowel syndrome - Pathophysiology, diagnosis, and treatment

American Journal of Therapeutics

Volumn 7, Issue 4, 2000, Pages 265-272

  Schwartz, Darren ^a   Stollman, Neil ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Abdominal pain; Constipation; Diarrhea; Functional bowel disorders; Intestinal motility; Irritable bowel syndrome; Visceral hypersensitivity

Indexed keywords

ADULT; CASE REPORT; FEMALE; HUMAN; IRRITABLE COLON; PATHOPHYSIOLOGY; REVIEW;

ADULT; COLONIC DISEASES, FUNCTIONAL; FEMALE; HUMANS;

EID: 0034252380     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200007040-00007     Document Type: Article

References (46)

1. Drossman DA, Zhiming L, Andruzzi E, et al: U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569.
2. Talley NJ, Zinsmeister AR, Melton LJ III: Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142:76-83.
3. Drossman DA: U.S. national prevalences of functional gastrointestinal disorders. In: Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. (Eds. Drossman DA, Richter JE, et al). Little Brown, Boston, 1994, p313.
4. Lydiard RB: Anxiety and irritable bowel syndrome: psychiatric, medical, or both? J Clin Psychiatry 1997;58 (Suppl III):51-58.
5. Russo MW, Gaynes BN, Drossman DA: What the gastroenterologist does all day: a decade later. Gastroenterology 1998;114:A37.
6. Lasser RB, Bond JH, Levitt MD: The role of intestinal gas in functional abdominal pain. N Engl J Med 1975;293: 524.
7. Francis CY, Whorwell PJ: The irritable bowel syndrome. Postgrad Med 1997;73:1-7.
8. Accarino AM, Azpiroz F, Malagelada JR: Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995;108:636-643.
9. Whitehead WE: Effects of psychological factors on gastrointestinal function. In: Pathogenesis of Functional Bowel Disease. (Ed. Snape WJ Jr). Plenum, New York, 1989.
10. Kellow JE, Phillips SF: Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987;92:1885-1893.
11. Kellow JE, Eckersley CM, Jones MP: Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991;10:1621-1627.
12. Munakata J, Naliboff B, Harraf F, et al: Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112:55-63.
13. Fukudo S, Nomura T, Muranaka, et al: Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome: a preliminary study. J Clin Gastroenterol 1993;17:133-141.
14. Drossman DA: Irritable bowel syndrome. Gastroenterologist 1994;2:315-326.
15. Almounajed G, Drossman DA: Newer aspects of the irritable bowel syndrome. Gastroenterology 1996;23:477-495.
16. Drossman DA: Psychosocial factors in the care of patients with gastrointestinal disorders. In: Textbook of Gastroenterology. (Ed. Yamada T). JB Lippincott, Philadelphia, 1995, pp620-637.
17. Bearcroft CP, Perrett D, Farthing MJ: Postprandial plasma 5-hydroxytryptamine in diarrhea predominant irritable bowel syndrome: a pilot study. Gut 1998;42:42-46.
18. Snape WJ Jr: Irritable bowel syndrome. In: Bockus Gastroenterology. (Eds. Haubrick WS, Schaffner F). W.B. Saunders, Philadelphia, 1995, pp1619-1636.
19. Lind CD: Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 1991;20:279-295.
20. Small PK, Loudon MA, Hau CM, et al: Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Scand J Gastroenterol 1997;32: 39-47.
21. Kellow JE, Phillips SF, Miller LJ, et al: Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988; 29:1236-1243.
22. Drossman DA, Mckee DC, Sandler RS, et al: Psychological factors in the irritable bowel syndrome: a multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988;95:701-708.
23. Talley NJ, Boyce PM, Jones M: Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut 1997;41:394-398.
24. Gick ML, Thompson WG: Negative affect and the seeking of medical care in university students with irritable bowel syndrome: a preliminary study. J Psychosomatic Res 1997;43:535-540.
25. Drossman DA, Leserman J, Nachman G, et al: Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113: 828-833.
26. Elam M, Swensson THE, Thoreu P: Locus ceruleus in sympathetic nerves: activation of visceral afferents. Brain Res 1986;375:117-125.
27. Williams CL, Peterson JM, Villar RG, et al: Corticotropin-releasing factor directly mediates colonic response to stress. Am J Physiol 1987;253:G582-G586.
28. Thompson DG, Laidlow JM, Wingate DL: Abnormal small-bowel motility demonstrated by radiotelemetry in a patient with irritable colon. Lancet 1979;2:1321-1323.
29. Kumar D, Wingate DL: The irritable bowel syndrome: a paroxysmal motor disorder. Lancet 1985;2:973-977.
30. Thompson GW: Functional bowel disorders and functional abdominal pain. In: Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. (Eds. Drossman DA, Richter JE, et al). Little Brown, Boston, 1994, pp120-121.
31. Thompson GW: Functional bowel disorders and functional abdominal pain. In: Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. (Eds. Drossman DA, Richter JE, et al). Little Brown, Boston, 1994, p142.
32. Moeller HC: Treatment of irritable colon. Mod Treat 1965;2:988-1002.
33. Lynn RB, Friedman LS: Irritable bowel syndrome: managing the patient with abdominal pain and altered bowel habits. Med Clin North Am 1995;79:373-390.
34. Francis CY, Whorwell PJ: Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994;344:39-40.
35. Farup PG, Hovdenak N, Wetterhus S, et al: The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998;33:128-131.
36. Talley NJ, Owen BK, Boyce P, et al: Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-286.
37. Chan J, Carr I, Mayberry JF: The role of acupuncture in the treatment of irritable bowel syndrome: a pilot study. Hepato Gastroenterol 1997;44:1328-1330.
38. Dapoigny M, Abitbol JL, Fraitag B: Efficacy of peripheral kappa agonist fedotozine versus placebo in irritable bowel syndrome: a multicenter dose-response study. Dig Dis Sci 1995;40:2244-2249.
39. Baldi F, Braucaccio ML, Cappiello R: Fedotozine increases the threshold of colonic visceral perception in irritable bowel syndrome (abstract). Gastroenterology 1998;114:A715.
40. Read NW, Abitbol JL, Bardhan KD, et al: Efficiency and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997;41:664-668.
41. Sanger GJ: 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol Motil 1996;8:319-331.
42. Goldberg PA, Kamm MA, Setti-Carravo P, et al: Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996;57:478-483.
43. Northcutt AR, Camilleri M, Mayer EA, et al: Alosetron, a 5HT3-receptor antagonist is effective in the treatment of female irritable bowel syndrome patients (abstract). Gastroenterology 1998;114:A812.
44. Houghton LA, Jackson NA, Whorwell PJ, et al: 5-HT4 antagonism in irritable bowel syndrome (IBS): effect of S13-207266-A on rectal sensitivity and small bowel transit (abstract). Gastroenterology 1998;114:A812.
45. Houghton LA, Rogers J, Whorwell PJ, et al: Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome. Alim Pharm Ther 1997;11: 561-568.
46. Bradette M, Delvaux M, Staulmont G, et al: Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sciences 1994;39:1171-1178.